All News #Library
Rare Diseases
Quince Therapeutics Exceeds 75% Enrollment in Phase 3 NEAT Trial
03 Jun 2025 //
BUSINESSWIRE
Quince’s EryDex Long-Term Safety Data Publish in Neurology Journal
27 Jan 2025 //
BUSINESSWIRE
FDA fast tracks Quince Therapeutics’ rare ataxia drug EryDex
04 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Quince buys a rare disease biotech
24 Jul 2023 //
ENDPTS